Statistical Methods for High Dimensional Biology STAT/BIOF/GSAT 540

Human Genetics & GWAS

Keegan Korthauer 24 March 2021

With slide contributions from Sara Mostafavi

Announcements

- Analysis Assignment due Monday (29 March)
- Next week's lectures (29 and 31 March our last! 6) will both be synchronous
 - Guest lecturer **Dr.Yongjin Park** will be back with us to talk about causal inference in genomics on Monday
 - Guest lecturer **Dr. Jessica Dennis** will be with us to talk about polygenic risk scores and phenome-wide association studies on Wednesday
- Project presentations will take place during the last 3 class sessions (all synchronous)
 - Reminder that these Zoom sessions will be recorded (only made available to registered students in the course through canvas)
 - Peer review assignments for individual reports will be announced next week

Learning objectives

- Describe properties of genetic variants in terms of their prevalence in the population, and the likelihood of its effect using relevant terminology (e.g. SNV vs SNP, allele, penetrance)
- Explain the "Common Disease-Common Variant" hypothesis and its implications
- Understand the purpose of Genome-Wide Association Studies (GWAS)
- List two commonly used statistical approaches for GWAS analysis and describe advantages / disadvantages of each
- Understand the main mathematical ideas behind Chi square testing and logistic regression

Outline

Terminology and fundamentals

Human genetics and disease


- GWAS genome-wide association studies
 - Statistical testing: chi-square test/logistic regression

Human genetic differences are common




Many of these differences are heritable (passed on from parents to offspring)

Recall: definitions




- Every (nucleated) cell has a complete copy of the genome (DNA)
- Gene: a segment of DNA that has a "function"
- Genotype: genetic makeup of an individual
- Phenotype: observable trait
- **Genetic association**: relationship between genotype and phenotype

"Genome: bought the book; hard to read." -Eric Lander



CATGACGTCGCGGACAACCCAGAATTGTCTTGAGCGATGGTAAGATCTAACCTCACTGCCGGGGGAGGCTCATAC CTGGGGCTTTACTGATGTCATACCGTCTTGCACGGGGATAGAATGACGGTGCCCGTGTCTGCTTGCCTCGAAGCA ATTTTCTGAAAGTTACAGACTTCGATTAAAAAGATCGGACTGCGCGTGGGCCCGGAGAGACATGCGTGGTAGTCA TTTTTCGACGTGTCAAGGACTCAAGGGAATAGTTTGGCGGGAGCGTTACAGCTTCAATTCCCAAAGGTCGCAAGA CGATAAAATTCAACTACTGGTTTCGGCCTAATAGGTCACGTTTTATGTGAAATAGAGGGGAACCGGCTCCCAAAT CCCTGGGTGTTCTATGATAAGTCCTGCTTTATAACACGGGGCGGTTAGGTTAAATGACTCTTCTATCTTATGGTG ATCCAAGCGCCCGCTAATTCTGTTCTGTTAATGTTCATACCAATACTCACATCACATTAGATCAAAGGATCCCCG AGCCCAGTCGCAAGGGTCTGCTGCTGTTGTCGACGCCTCATGTTACTCCTGGAATCTACCTGCCCTCCCCTCACC AGACAACCTAACTAATAGTCTCTAACGGGGAATTACCTTTACCAGTCTCATGCCTCCAATATATCTGCACCGCTT CAATGATATCGCCCACAGAAAGTAGGGTCTCAGGTATCGCATACGCCGCGCCCGGGTCCCAGCTACGCTCAGGAC GACAGTAGAGAGCTATTGTGTAATTCAGGCTCAGCATTCATCGACCTTTCCTGTTGTGAATATTGTGCTAATGCA TCTCGTCCGTAACGATCTGGGGGGCAAAACCGAATATCCGTATTCTCGTCCTACGGGTCCACAATGAGAAAGTCC TGCGCGTGATCGTCAGTTAAGTTAAATTCAGGCTACGGTAAACTTGTAGTGAGCTAAGAATCACGGGAATC ACGGGTTCGCTACAGATGAACTGAATTTATACACGGACAACTCATCGCCCATTTGGGCGTGGGCACCGCAGATCA AAAGTGGCAGATTAGGAGTGCTTGATCAGGTTAGCAGGTGGACTGTATCCAACAGCGCATCAAACTTCAATAAAT CCAAAGCGTTGTAGTGGTCTAAGCACCCCTGAACAGTGGCGCCCATCGTTAGCGTAGTACAACCCTTCCCCCTTG AGGTGCGACATGGGGCCAGTTAGCCTGCCCTATATCCCTTGCACACGTTCAATAAGAGGGGCTCTACAGCGCCGC TTTTTAAATTAGGATGCCGACCCCATCATTGGTAACTGTATGTTCATAGATATTTCTTCAGGAGTAATAGCGACA AGCTGACACGCAAGGGTCAACAATAATTTCTACTATCACCCCGCTGAACGACTGTCTTTGCAAGAACCAACTGGG CTTAGATTCGCGTCCTAACGTAGTGAGGGCCGAGTCATATCATAGATCAGGCATGAGAAACCGACGTCGAGTCTA CACACGAGTTGTAAACAACTTGATTGCTATACTGTAGCTACCGCAAGGATCTCCTACATCAAAGACTACTGGGCG ATCTGGATCCGAGTCAGAAATACGAGTTAATGCAAATTTACGTAGACCGGTGAAAACACGTGCCATGGGTTGCGT AGACCGTAGTCAGAAGTGTGGCGCGCTATTCGTACCGAACCGGTGGAGTATACAGAATTGCTCTTCTACGACGTA AGGAGCTCGGTCCCCAATGCACGCCAAAAAAGGAATAAAGTATTCAAACTGCGCATGGTCCCTCCGCCGGTGGCA CTATTATCCATCCGAACGTTGAACCTACTTCCTCGGCTTATGCTGTCCTCAACAGTATCGCTTATGAATCGCATG ACTAAGTTATCCAGATCAAGGTTTGAACGGACTCGTATGACATGTGTGACTGAACCCGGGAGGAAATGCAGAGAA CTGTTTCAAGGCCTCTGCTTTGGTATCACTCAATATATTCAGACCAGACAAGTGGCAAAATTTCGTGCGCCTCTC CTAGGTATTCACGCAACCGTCGTAACATGCACTAAGGATAACTAGCGCCAGGGGGGCATACTAGGTCCCGGAGCT AAAGACTACCCTATGGATTCCTTGGAGCGGGGACAATGCAGACCGGTTACGACACAATTATCGGGATCGTCTAGA GTGTTGGGTCGGGCAAGTCCCCGAAGCTCGGCCAAAAGATTCGCCATGGAACCGTCTGGTCCTGTTAGCGTGTAC GCCTGCTCCTGTTCCGGGTACCATAGATAGACTGAGATTGCGTCAAAAAATTGCGGCGAAAATAGAGGGGCTCCT TGTAGAAATACCAGACTGGGGAATTTAAGCGCTTTCCACTATCTGAGCGACTAAACATCAACAAAATGCGTCTACT CGAATCCGCAGTAGGCAATTACAACCTGGTTCAGATCACTGGTTAATCAGGGATGTCTTCATAAGATTATACTTG CCCCGACGCGACAGCTCTTCAAGGGGCCGATTTTTGGACTTCAGATACGCTAGAATTTAAAGGGTCTCTTACACC TGCTGCGGCCTGCAGGGACCCCTAGAACTTGCCGCCTACTTGTCTCAGTCTAATAACGCGCGAAGCCGTGGGGCA CGTGACCTTAAGTCGCAGAGCGAGTGATGAATTTGGGACGCTAATATGGGTGAATAGAGACTTATATCATCAGGG


"Genome: bought the book; hard to read." -Eric Lander




CATGACGTCGCGGACAACCCAGAATTGTCTTGAGCGATGGTAAGATCTAACCTCACTGCCGGGGGAGGCTCATAC CTGGGGCTTTACTGATGTCATACCGTCTTGCACGGGGATAGAATGACGGTGCCCGTGTCTGCTTGCCTCGAAGCA ATTTTCTGAAAGTTACAGACTTCGATTAAAAAGATCGGACTGCGCGTGGGCCCGGAGAGACATGCGTGGTAGTCA TTTTTCGACGTGTCAAGGACTCAAGGGAATA<mark>GTTTGGCGGGAG</mark>CGTTACAGCTTCAATTCCCAAAGGTCGCAAGA CGATAAAATTCAACTACTGGTTTCGGCCTAATAGGTCACGTTTTATGTGAAATAGAGGGGAACCGGCTCCCAAAT CCCTGGGTGTTCTATGATAAGTCCTGCTTTATAACACGGGGCGGTTAGGTTAAATGACTCTTCTATCTTATGGTG ATCCAAGCGCCCGCTAATTCTGTTCTGTTAATGTTCATACCAATACTCACATCACATTAGATCAAAGGATCCCCG AGCCCAGTCGCAAGGGTCTGCTGCTGTTGTCGACGCCTCATGTTACTCCTGGAATCTACCTGCCCTCCCCTCACC AGACAACCTAACTAATAGTCTCTAACGGGGAATTACCTTTACCAGTCTCATGCCTCCAATATATCTGCACCGCTT CAATGATATCGCCCACAGAAAGTAGGGTCTCAGGTATCGCATACGCCGCGCCCGGGTCCCAGCTACGCTCAGGAC GACAGTAGAGAGCTATTGTGTAATTCAGGCTCAGCATTCATCGACCTTTCCTGTTGTGAATATTGTGCTAATGCA TCTCGTCCGTAACGATCTGGGGGGCAAAACCGAATATCCGTATTCTCGTCCTACGGGTCCACAAITGAGAAAGTCC TGCGCGTGATCGTCAGTTAAGTTAAATTCAGGCTACGGTAAACTTGTAGTGAGCTAAGAATCACGGGAATC ACGGGTTCGCTACAGATGAACTGAATTTATACACGGACAACTCATCGCCCATTTGGGCGTGGGCACCGCAGATCA AAAGTGGCAGATTAGGAGTGCTTGATCAGGTTAGCAGGTGGACTGTATCCAACAGCGCATCAAACTTCAATAAAT CCAAAGCGTTGTAGTGGTCTAAGCACCCCTGAACAGTGGCGCCCATCGTTAGCGTAGTACAACCCTTCCCCCTTG AGGTGCGACATGGGGCCAGTTAGCCTGCCCTATATCCCTTGCACACGTTCAATAAGAGGGGCTCTACAGCGCCGC TTTTTAAATTAGGATGCCGACCCCATCATTGGTAACTGTATGTTCATAGATATTTCTTCAGGAGTAATAGCGACA AGCTGACACGCAAGGGTCAACAATAATTTCTACTATCACCCCGCTGAACGACTGTCTTTGCAAGAACCAACTGGG CTTAGATTCGCGTCCTAACGTAGTGAGGGCCGAGTCATATCATAGATCAGGCATGAGAAACCGACGTCGAGTCTA CACACGAGTTGTAAACAACTTGATTGCTATACTGTAGCTACCGCAAGGATCTCCTACATCAAAGACTACTGGGCG -ATCTGGATCCGAGTCAGAAATACGAGTTAATGCAAATTTACGTAGACCGGTGAAAACACGTGCCATGGGTTGCGT AGACCGTAGTCAGAAGTGTGGCGCGCTATTCGTACCGAACCGGTGGAGTATACAGAATTGCTCTTCTACGACGTA AGGAGCTCGGTCCCCAATGCACGCCAAAAAAGGAATAAAGTAT<u>TCAAACTGCGCATGGTCCCTCCGCCGGT</u>GGCA CTATTATCCATCCGAACGTTGAACCTACTTCCTCGGCTTATGCTGTCCTCAACAGTATCGCTTATGAATCGCATG ACTAAGTTATCCAGATCAAGGTTTGAACGGACTCGTATGACATGTGTGACTGAACCCGGGAGGAAATGCAGAGAA CTGTTTCAAGGCCTCTGCTTTGGTATCACTCAATATATTCAGACCAGACAAGTGGCAAAATTTCGTGCGCCTCTC CTAGGTATTCACGCAACCGTCGTAACATGCACTAAGGATAACTAGCGCCAGGGGGGCATACTAGGTCCCGGAGCT AAAGACTACCCTATGGATTCCTTGGAGCGGGGACAATGCAGACCGGTTACGACACAATTATCGGGATCGTCTAGA GTGTTGGGTCGGGCAAGTCCCCGAAGCTCGGCCAAAAGATTCGCCATGGAACCGTCTGGTCCTGTTAGCGTGTAC GCCTGCTCCTGTTCCGGGTACCATAGATAGACTGAGATTGCGTCAAAAAATTGCGCGAAAAATAGAGGGGCTCCT TGTAGAAATACCAGACTGGGGAATTTAAGCGCTTTCCACTATCTGAGCGACTAAACATCAACAAATGCGTCTACT CGAATCCGCAGTAGGCAATTACAACCTGGTTCAGATCACTGGTTAATCAGGGATGTCTTCATAAGATTATACTTG CCCCGACGCGACAGCTCTTCAAGGGGCCGATTTTTGGACTTCAGATACGCTAGAATTTAAAGGGTCTCTTACACC TGCTGCGGCCTGCAGGGACCCCTAGAACTTGCCGCCTACTTGTCTCAGTCTAATAACGCGCGAAGCCGTGGGGCA CGTGACCTTAAGTCGCAGAGCGAGTGATGAATTTGGGACGCTAATATGGGTGAATAGAGACTTATATCATCAGGG

gene

"Genome: bought the book; hard to read." -Eric Lander



CATGACGTCGCGGACAACCCAGAATTGTCTTGAGCGATGGTAAGATCTAACCTCACTGCCGGGGGAGGCTCATAC CTGGGGCTTTACTGATGTCATACCGTCTTGCACGGGGATAGAATGACGGTGCCCGTGTCTGCTTGCCTCGAAGCA ATTTTCTGAÄAGTTACAGACTTCGATTAAAAAGATCGGACTGCGCGTGGGCCCGGAGAGACATGCGTGGTAGTCA TTTTTCGACGTGTCAAGGACTCAAGGGAATA<mark>GTTTGGCGGGAG</mark>CGTTACAGCTTCAATTCCCAAAGGTCGCAAGA CGATAAAATTCAACTACTGGTTTCGGCCTAATAGGTCACGTTTTATGTGAAATAGAGGGGAACCGGCTCCCAAAT CCCTGGGTGTTCTATGATAAGTCCTGCTTTATAACACGGGGCGGTTAGGTTAAATGACTCTTCTATCTTATGGTG ATCCAAGCGCCCGCTAATTCTGTTCTGTTAATGTTCATACCAATACTCACATCACATTAGATCAAAGGATCCCCG AGCCCAGTCGCAAGGGTCTGCTGCTGTTGTCGACGCCTCATGTTACTCCTGGAATCTACCTGCCCTCCCCTCACC AGACAACCTAACTAATAGTCTCTAACGGGGAATTACCTTTACCAGTCTCATGCCTCCAATATATCTGCACCGCTT CAATGATATCGCCCACAGAAAGTAGGGTCTCAGGTATCGCATACGCCGCGCCCGGGTCCCAGCTACGCTCAGGAC GACAGTAGAGAGCTATTGTGTAATTCAGGCTCAGCATTCATCGACCTTTCCTGTTGTGAATATTGTGCTAATGCA TCTCGTCCGTAACGATCTGGGGGGCAAAACCGAATATCCGTATTCTCGTCCTACGGGTCCACAAITGAGAAAGTCC TGCGCGTGATCGTCAGTTAAGTTAAATTCAGGCTACGGTAAACTTGTAGTGAGCTAAGAATCACGGGAATC ACGGGTTCGCTACAGATGAACTGAATTTATACACGGACAACTCATCGCCCATTTGGGCGTGGGCACCGCAGATCA AAAGTGGCAGATTAGGAGTGCTTGATCAGGTTAGCAGGTGGACTGTATCCAACAGCGCATCAAACTTCAATAAAT CCAAAGCGTTGTAGTGGTCTAAGCACCCCTGAACAGTGGCGCCCATCGTTAGCGTAGTACAACCCTTCCCCCTTG AGGTGCGACATGGGGCCAGTTAGCCTGCCCTATATCCCTTGCACACGTTCAATAAGAGGGGCTCTACAGCGCCGC TTTTTAAATTAGGATGCCGACCCCATCATTGGTAACTGTATGTTCATAGATATTTCTTCAGGAGTAATAGCGACA AGCTGACACGCAAGGGTCAACAATAATTTCTACTATCACCCCGCTGAACGACTGTCTTTGCAAGAACCAACTGGG CTTAGATTCGCGTCCTAACGTAGTGAGGGCCGAGTCATATCATAGATCAGGCATGAGAAACCGACGTCGAGTCTA CACACGAGTTGTAAACAACTTGATTGCTATACTGTAGCTACCGCAAGGATCTCCTACATCAAAGACTACTGGGCG ATCTGGATCCGAGTCAGAAATACGAGTTAATGCAAATTTACGTAGACCGGTGAAAACACGTGCCATGGGTTGCGT AGACCGTAGTCAGAAGTGTGGCGCGCTATTCGTACCGAACCGGTGGAGTATACAGAATTGCTCTTCTACGACGTA AGGAGCTCGGTCCCCAATGCACGCCAAAAAAGGAATAAAGTAT<u>TCAAACTGCGCATGGTCCCTCCGCCGGT</u>GGCA CTATTATCCATCCGA4CGTTGAACCTAdTTCCTCGGCTTATGCTCTCAACAGTATCGCTTATGAATCGCATG ACTAAGTTATCCAGATCAAGGTTTGAACGGACTCGTATGACATGTGTGACTGAACCCGGGAGGAAATGCAGAGAA CTGTTTCAAGGCCTCTGCTTTGGTATCACTCAATATATTCAGACCAGACAAGTGGCAAAATTTCGTGCGCCTCTC CTAGGTATTCACGCAACCGTCGTAACATGCACTAAGGATAACTAGCGCCAGGGGGGCATACTAGGTCCCGGAGCT AAAGACTACCCTATGGATTCCTTGGAGCGGGGACAATGCAGACCGGTTACGACACAATTATCGGGATCGTCTAGA GTGTTGGGTCGGGCAAGTCCCCGAAGCTCGGCCAAAAGATTCGCCATGGAACCGTCTGGTCCTGTTAGCGTGTAC GCCTGCTCCTGTTCCGGGTACCATAGATAGACTGAGATTGCGTCAAAAAAATTGCGGCGAAAATAGAGGGGCTCCT TGTAGAAATACCAGACTGGGGAATTTAAGCGCTTTCCACTATCTGAGCGACTAAACATCAACAAATGCGTCTACT CGAATCCGCAGTAGGCAATTACAACCTGGTTCAGATCACTGGTTAATCAGGGATGTCTTCATAAGATTATACTTG CCCCGACGCGACAGCTCTTCAAGGGGCCGATTTTTGGACTTCAGATACGCTAGAATTTAAAGGGTCTCTTACACC TGCTGCGGCCTGCAGGGACCCCTAGAACTTGCCGCCTACTTGTCTCAGTCTAATAACGCGCGAAGCCGTGGGGCA CGTGACCTTAAGTCGCAGAGCGAGTGATGAATTTGGGACGCTAATATGGGTGAATAGAGACTTATATCATCAGGG




Some more terminology and statistics

- 3 billion (3b) bases in human DNA
- A variant is a "base" that is different between individuals
- ~50% from each parent
- ~60 "new/acquired" variants compared to parents
- ~0.6% different between individuals from same population²

https://www.nature.com/articles/ng.862 (2011)

² https://www.nature.com/articles/nature I 5393 (2015)

Alleles



Review: SNPs vs SNVs

Common vs rare variants

- Single nucleotide polymorphisms (SNPs) vs single nucleotide variants (SNVs)
 - Common: more than 1% in population
 - Rare: less than 1% in population
- Other types of variation: structural variation, insertion/deletion, duplication

Outline

Terminology and fundamentals

Human genetics and disease

- GWAS genome-wide association studies
 - Statistical testing: chi-square test/logistic regression


Genetic studies

• Cross-species: which genetic differences result in observed differences between different species (e.g. phylogenetic)


• Within-species: which genetic differences result in observed differences within a species (e.g. traits/phenotypes)

 Today: a particular type of within-species comparisons called Genome-wide association studies


How does genetic disease arise?



How does genetic disease arise?



How does genetic disease arise?



Note: not perfect **penetrance**

Terminology so far:

- Base
- Variant
- SNP
- SNV
- Allele
- Genotype
- Penetrance

Heritable disease/phenotype/traits

Some examples:


- -TID
- Schizophrenia
- Multiple Sclerosis

- Sickle Cell Anemia
- Tay—Sachs disease

Common disease-common variant hypothesis

- Rare disease: very rare variants ("mutations") in one or a very small number of loci/genes.
- Common disease: influenced by variants that are common in the population (e.g., SNPs)
 - Also implies that the effect size for each variant should be small and that multiple variants must be at play
- The same study design will not be successful for both types of diseases
 - Implies that family studies unlikely to be successful and need to assess disease association in population studies

Common disease-common variant hypothesis



Genetic study considerations:

- Feasibility of identifying genetic variants by risk allele
- Frequency and strength of genetic effect (odds ratio)

Heritable human traits

- Rare/simple ("Mendelian") disease

- One or small number of loci
- Inheritance pattern is clear (e.g. recessive loss/gain of function, autosomal dominant, X-linked)
- Qualitative/discrete differences

Complex/common disease

- Multiple genetic factors contribute
- Mendelian ratios are not applicable; need a different method for studying them
- Environmental factors are also at play
- Genetic inheritance is not simple to understand/predict

Why do we want to look at genetics vs gene expression?

Outline

Terminology and fundamentals

Human genetics and disease

- GWAS genome-wide association studies
 - Statistical testing: chi-square test/logistic regression


What is a GWAS?

- Genome-Wide Association Study study interrogating the relationship between genome-wide genetic variation and a phenotype.
- GWAS: experimental design + type of data
- Characteristics
 - Case control study design
 - Large number of samples (n > 10K)
 - Standardized QC, and Imputation
 - Standardized statistical tests and multiple testing correction
 - Much of the data is 'negative'

A little bit of history

- 2001: a draft of the human genome sequence becomes available
- 2001:The international SNP Map Working Group publishes a SNP Map of 1.42 million SNPs that contained all SNPs identified so far
- 2005: HapMap project Phase I starts:
 - Genotype at least one common SNP (MFAF>5%) every 5Kb across 270 individuals
 - Geographical diversity
 - I.3 million SNPs
- 2012: 1,000 Genomes project completed
- 2018: 100,000 Genomes project completed


The "\$1,000 genome" is here




Primary tool of GWAS: Genotyping arrays

 Platforms: Illumina and Affymetrix

~IM – 5M"genotyped" SNPsper array



Welcome to the era of GWAS!



Genotyping: measure a large set of pre-determined SNPs

GWAS studies' amazing success since 2005

- Prior to invention of GWAS, there was very little success in identifying genetic sources of common heritable disease
- GWAS studies have identified hundreds to thousands of genetic risk loci for complex diseases like SCZ, MDD, T2D






Review

10 Years of GWAS Discovery: Biology, Function, and Translation

Peter M. Visscher ^{1, 2} ≈ M. Naomi R. Wray ^{1, 2}, Qian Zhang ¹, Pamela Sklar ³, Mark I. McCarthy ^{4, 5, 6}, Matthew A. Brown ⁷, Jian Yang ^{1, 2}


GWAS studies' amazing success since 2005



In Practice

Most SNPs are bialleleic (major and minor allele)

Data representation: count the number of minor alleles at each site



Out of scope

- QC process
 - Sample quality
 - Sex inconsistency
 - HW concordance
 - Base calling quality
 - Genomic inflation/population stratification (later)
- Imputation of additional SNPs
 - LD: linkage disequilibrium
 - Typically impute ~5M additional SNPs



in Human Genetics

UNIT

Quality Control Procedures for Genome-Wide Association Studies

Stephen Turner, Loren L. Armstrong, Yuki Bradford, Christopher S. Carlson, Dana C. Crawford, Andrew T. Crenshaw, Mariza de Andrade, Kimberly F. Doheny, Jonathan L. Haines ... See all authors V

Published: 22 July 2012

Fast and accurate genotype imputation in genomewide association studies through pre-phasing

Bryan Howie, Christian Fuchsberger, Matthew Stephens ☑, Jonathan Marchini ☑ & Gonçalo R Abecasis ☑

Nature Genetics 44, 955–959(2012) | Cite this article
2214 Accesses | 1028 Citations | 24 Altmetric | Metrics

Study design and statistics in GWAS

Study design:

- Case/control design (binary disease/healthy outcome)
- Some studies also look at continuous outcomes (e.g. BMI, height)
- Genotype at several million SNPs

Statistics:

- Chi-Square test
- Logistic regression to compute log odds
- One SNP at a time

Why not just use ANOVA/linear regression?

- Linear regression models E(Y) as a linear function X
 - What is Y (response) in a case/control GWAS?

- Recall the **assumptions**:
 - normality
 - constant variance

Contingency tables

- We are interested in the relationship between two categorical variables with k and m levels
- We want to know whether the probability of one being in case/control class is statistically dependent on the allele
- Contingency table: count the number of subjects in combination of levels from each category

	Case	Control
Minor allele (Allele A)	a	b
Major allele (Allele G)	С	d

Contingency tables

- We are interested in the relationship between two categorical variables with k and m levels
- We want to know whether the probability of one being in case/control class is statistically dependent on the allele
- Contingency table: count the number of subjects in combination of levels from each category

	Case	Control	Row total
Minor allele (A)	a	b	a + b
Major allele (G)	С	d	c + d
Column total	a + c	b + d	a + b + c + d


Example: Age related macular degeneration



image source: neoretina.com/blog/a-simple-guide-to-understanding-age-related-macular-degeneration/

Relative risk plotted as a function of the genetic load of the 5 variants that influence the risk of AMD

Maller et al. (2006): https://www.nature.com/articles/ng1873



- 2004: Little known about the cause of AMD
- 2006: GWAS discovers 3 genes (5 common variants) that explain >50% of risk

Example: contingency table from AMD GWAS

	Case	Control	Row total
Allele A	1522	670	2192
Allele G	954	1198	2152
Column total	2476	1868	4344

The probabilities of each alleles in

The probabilities of each alleles in
$$P(A \mid Case) = 1522 / 2476 \sim 61\%$$
 cases and controls looks different: $P(A \mid Control) = 670 / 1868 \sim 35\%$

Contingency tables- Chi-Square test

	Case	Control	Row total
Allele A	1522	670	2192
Allele G	954	1198	2152
Column total	2476	1868	4344

Chi-square (χ^2) statistic: sum of squared differences between observed value in each cell and its expected value

$$\chi^{2} = \sum_{i=1}^{k} \sum_{j=1}^{m} \frac{(\text{Observed}_{ij} - \text{Expected}_{ij})^{2}}{\text{Expected}_{ij}}$$

Distribution of χ^2 statistic is known from theory: under the null, it follows a χ^2 distribution with (k-I)(m-I) df

Expected counts

Intuition: conditional on row and column totals, what do we expect under the null (i.e. if there's no association)?

	Case	Control	Row total	
Allele A			2192 ←	2192 / 4344 = 50%
Allele G			2152	
Column total	2476	1868	4344	
	2476 / 4344 =	= 57%	•	•

If 57% of samples are Cases, and 50% of samples have allele A, how many Cases do we expect to have allele A under the null?

Expected counts

	Case	Control	Row total
Allele A	RI x CI / N	RI x C2 / N	RI = 2192
Allele G	R2 x C1 / N	R2 x C2 / N	R2 = 2152
Column total	CI = 2476	C2 = 1868	N = 4344

Expected counts

Observed	Case	Control	Row total
Allele A	1522	670	2192
Allele G	954	1198	2152
Column total	2476	1868	4344

Expected	Case	Control	Row total
Allele A	1249	943	2192
Allele G	1227	925	2152
Column total	2476	1868	4344

Chi-square statistic

Observed	Case	Control
Allele A	1522	670
Allele G	954	1198

Expected	Case	Control
Allele A	1249	943
Allele G	1227	925

$$\chi^{2} = \sum_{i=1}^{k} \sum_{j=1}^{m} \frac{(\text{Observed}_{ij} - \text{Expected}_{ij})^{2}}{\text{Expected}_{ij}}$$

$$\chi^2 = 279.2$$

$$df = (2 - 1) * (2 - 1) = 1$$

$$p - value = 1.2 \times 10^{-62}$$


Note that R returns 0 for 1-pchisq(279.2, 1) (See also chisq.test())

Chi-square test

- Simple one loci at a time test
- Rigid doesn't naturally allow investigating more than two variables at a time...

Logistic regression

- A Generalized Linear Model (GLM) for a binary outcome (e.g. case-control)
- Allows for inclusion of quantitative and/or categorical variables, or (nonlinear) function of your variables (e.g., log(x))



Logistic regression

Instead of modeling E(Y), we are modeling logit(E(Y)):

$$\log\left(\frac{E(Y)}{1-E(Y)}\right) = \log\left(\frac{p(Y=1)}{1-p(Y=1)}\right) = \beta_0 + \beta_1 x_1 + \dots + \beta_p x_p$$

logit = Log odds of "success"

Odds of "success"

• Odds: ratio of probability of success to probability of failure

odds
$$(Y = 1) = \frac{p(Y = 1)}{p(Y = 0)} = \frac{p(Y = 1)}{1 - p(Y = 1)}$$

- If odds = I, probability of success and failure are equal
 - we model log odds because this quantity is symmetric about 0
- If success rate is 0.9, then odds = 0.9/0.1 = 9 (i.e. for every nine successes there is one failure)
 - If we observe 25% success rate, what's the odd of success?
 - What about for an 75% success rate?
 - What are the log odds for both of these cases?

Parameters in logistic regression

- Hypothesis tests: Wald test for individual parameters, Likelihood ratio test for nested models
- Linear combination of parameters gives the log odds of success
- Intercept: log odds of success when all explanatory variables are 0
- One unit change in explanatory variable x_p changes log odds by \hat{eta}_p
 - Interpret parameters by converting back to odds or probability scale:

$$odds(Y = 1) = \frac{p(Y = 1)}{1 - p(Y = 1)} = e^{\widehat{\beta}_0 + \widehat{\beta}_1 x_1 + \dots + \widehat{\beta}_p x_p}$$
$$p(Y = 1) = \frac{e^{\widehat{\beta}_0 + \widehat{\beta}_1 x_1 + \dots + \widehat{\beta}_p x_p}}{1 + e^{\widehat{\beta}_0 + \widehat{\beta}_1 x_1 + \dots + \widehat{\beta}_p x_p}}$$

Fitting the logistic regression model

- Recall for OLS the parameters are the Maximum Likelihood Estimates (MLE)
 - Maximize the (normal) likelihood of the data given parameters
 - Equivalent to minimizing sum of squared errors
- Similarly for logistic regression, we want to maximize the likelihood of data given parameters (equivalent to maximizing log-likelihood)

$$L(Y|X,\beta) = \prod_{i=1}^{n} p(Y_i = 1)^{Y_i} (1 - p(Y_i = 1))^{1-Y_i}$$

$$\ell(\mathbf{Y}|\mathbf{x},\boldsymbol{\beta}) = \sum_{i=1}^{n} (Y_i \log(p(Y_i = 1)) + (1 - Y_i)\log(1 - p(Y_i = 1)))$$

Fitting the logistic regression model


Continued... (plugging in p(
$$Y_i = 1$$
) = $\frac{e^{\beta_0 + \beta_1 x_{i1} + \dots + \beta_p x_{ip}}}{1 + e^{\beta_0 + \beta_1 x_{i1} + \dots + \beta_p x_{ip}}}$)

$$\ell(Y|x,\beta) = \sum_{i=1}^{n} Y_i \log \left(\frac{e^{\beta_0 + \beta_1 x_{i1} + \dots + \beta_p x_{ip}}}{1 + e^{\beta_0 + \beta_1 x_{i1} + \dots + \beta_p x_{ip}}} \right) + \sum_{i=1}^{n} (1 - Y_i) \log \left(\frac{1}{1 + e^{\beta_0 + \beta_1 x_{i1} + \dots + \beta_p x_{ip}}} \right)$$

$$= \sum_{i=1}^{n} Y_i(\beta_0 + \beta_1 x_{i1} + \dots + \beta_p x_{ip}) - \sum_{i=1}^{n} \log(1 + e^{\beta_0 + \beta_1 x_{i1} + \dots + \beta_p x_{ip}})$$

Solving for $\widehat{\beta}$ that maximizes $\ell(Y|x,\beta)$ requires numerical methods (e.g., coordinate descent)

Manhattan plot



Significance in GWAS

- For determining which SNPs are "significant", it is conventional to assess genome-wide significance
- Typically, multiple correction is done with Bonferroni adjustment
 - recall from lecture 9 that this controls the FWER
 - recall that this is conservative (prob at least one error)
- Convention to use a p-value threshold of 5×10^{-8} (corresponds to Bonferroni adjustment for IM tests)
 - corresponds to estimates of the number of **independent** SNPs in human
- Recent research explores the use of FDR correction in GWAS
 - e.g. Brzyski et al. 2017

Summary of GWAS

- GWAS typically implies a study design and data type
 - Most commonly case-control and genotyping at several million SNPs
- Standardized steps for QC, and statistical analysis
 - Chi-square test/logistic regression
 - One SNP at a time analysis
 - Multiple testing correction (Bonferroni is the standard)
- Results: summary statistics; visualized with Manhattan plots
- Guest lectures next week:
 - Considering multiple genes at a time (polygenic risk scores)
 - Phenome-wide association studies
 - Causal inference